graeme kaufman

Cellmid biotechnology veteran Graeme Kaufman is non-executive director.

Kaufman brings more than 45 years of hands on experience in biotechnology spanning technical, commercial and financial areas.

Having worked for 34 years at CSL Limited (ASX: CSL), Australia’s largest biopharmaceutical company, he held senior positions including production director, general manager finance and general manager biosciences.

Kaufman’s responsibilities at CSL included corporate strategy and development as well as manufacturing, finance and marketing.

He was instrumental in the privatisation and ASX listing of CSL, including the negotiation of key contracts with stakeholders prior to listing.

Kaufman was formerly executive director of Circadian Technologies (ASX: CIR) and most recently senior vice president of corporate strategy at Mesoblast (ASX: MSB).

David King, chairman of Cellmid, commented: “Graeme has been an adviser to our senior management team for some years and has intimate knowledge of the midkine asset portfolio.”